{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:54:53Z","timestamp":1773388493490,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JPSP KAKENHI","award":["JP17H04144"],"award-info":[{"award-number":["JP17H04144"]}]},{"name":"Grant-in-Aid for Challenging","award":["19K22781"],"award-info":[{"award-number":["19K22781"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Infection is a major complication for patients with haematological malignancies. It is important to better understand the use of antimicrobial agents and antibiotic resistance for appropriate treatment and prevention of drug resistance. However, very few multi-centre analyses have focused on the use of antimicrobial agents and antibiotic resistance have been carried out in Japan. This study aimed to describe the characteristics of the use of antimicrobial agents and antibiotic resistance in patients with haematological malignancies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a cross-sectional study using administrative claims data and antimicrobial susceptibility data in Japan. We included patients diagnosed with haematological malignancies, who were hospitalized in a haematology ward between 1 April 2015 and 30 September 2017 in 37 hospitals. Descriptive statistics were used to summarize patient characteristics, antimicrobial utilization, bacterial infections, and antibiotic resistance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 8064 patients were included. Non-Hodgkin lymphoma (50.0%) was the most common malignancy. The broad-spectrum antibiotics displayed a following antimicrobial use density (AUD): cefepime (156.7), carbapenems (104.8), and piperacillin\/tazobactam (28.4). In particular, patients with lymphoid leukaemia, myeloid leukaemia, or myelodysplastic syndromes presented a higher AUD than those with Hodgkin lymphoma, non-Hodgkin lymphoma, or multiple myeloma. The most frequent bacterial species in our study cohort was <jats:italic>Escherichia coli<\/jats:italic> (9.4%), and this trend was also observed in blood specimens. Fluoroquinolone-resistant <jats:italic>E. coli<\/jats:italic> (3.6%) was the most frequently observed antibiotic-resistant strain, while other antibiotic-resistant strains were rare.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Broad-spectrum antibiotics were common in patients with haematological malignancies in Japan; however, antibiotic-resistant bacteria including carbapenem-resistant or multidrug-resistant bacteria were infrequent. Our results provide nationwide, cross-sectional insight into the use of antimicrobial agents, prevalence of bacteria, and antibiotic resistance, demonstrating differences in antimicrobial utilization among different haematological diseases.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12941-020-00348-0","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T16:09:04Z","timestamp":1581955744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Antimicrobial utilization and antimicrobial resistance in patients with haematological malignancies in Japan: a multi-centre cross-sectional study"],"prefix":"10.1186","volume":"19","author":[{"given":"Wataru","family":"Mimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhisa","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4112-6035","authenticated-orcid":false,"given":"Manabu","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,17]]},"reference":[{"key":"348_CR1","unstructured":"The Government of Japan. National Action Plan on Antimicrobial Resistance (AMR) 2016\u20132020. https:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-10900000-Kenkoukyoku\/0000138942.pdf. Accessed 27 July 2019."},{"key":"348_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4137\/PMC.S14459","volume":"6","author":"RJ Fair","year":"2014","unstructured":"Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem. 2014;6:25\u201364.","journal-title":"Perspect Medicin Chem."},{"key":"348_CR3","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/jac\/dkm514","volume":"61","author":"C Cattaneo","year":"2008","unstructured":"Cattaneo C, Quaresmini G, Casari S, Capucci MA, Micheletti M, Borlenghi E, Signorini L, Re A, Carosi G, Rossi G. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother. 2008;61:721\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"348_CR4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s10096-013-1819-7","volume":"32","author":"E Montassier","year":"2013","unstructured":"Montassier E, Batard E, Gastinne T, Potel G, de La Cochetiere MF. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis. 2013;32:841\u201350.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"348_CR5","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1017\/S0950268809991208","volume":"138","author":"CY Chen","year":"2010","unstructured":"Chen CY, Tsay W, Tang JL, Tien HF, Chen YC, Chang SC, Hsueh PR. Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiol Infect. 2010;138:1044\u201351.","journal-title":"Epidemiol Infect"},{"key":"348_CR6","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1586\/14787210.2013.836057","volume":"11","author":"P Viale","year":"2013","unstructured":"Viale P, Giannella M, Lewis R, Trecarichi EM, Petrosillo N, Tumbarello M. Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections. Expert Rev Anti Infect Ther. 2013;11:1053\u201363.","journal-title":"Expert Rev Anti Infect Ther."},{"key":"348_CR7","doi-asserted-by":"publisher","first-page":"e6959","DOI":"10.1097\/MD.0000000000006959","volume":"96","author":"J Ma","year":"2017","unstructured":"Ma J, Li N, Liu Y, Wang C, Liu X, Chen S, Xie X, Gan S, Wang M, Cao W, et al. Antimicrobial resistance patterns, clinical features, and risk factors for septic shock and death of nosocomial E coli bacteremia in adult patients with hematological disease: a monocenter retrospective study in China. Medicine. 2017;96:e6959.","journal-title":"Medicine"},{"key":"348_CR8","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3109\/23744235.2015.1051105","volume":"47","author":"O Kara","year":"2015","unstructured":"Kara O, Zarakolu P, Ascioglu S, Etgul S, Uz B, Buyukasik Y, Akova M. Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies. Infect Dis. 2015;47:686\u201393.","journal-title":"Infect Dis."},{"key":"348_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/QCO.0000000000000038","volume":"27","author":"EM Trecarichi","year":"2014","unstructured":"Trecarichi EM, Tumbarello M. Antimicrobial-resistant gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. Curr Opin Infect Dis. 2014;27:200\u201310.","journal-title":"Curr Opin Infect Dis."},{"key":"348_CR10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.3324\/haematol.2010.036640","volume":"96","author":"EM Trecarichi","year":"2011","unstructured":"Trecarichi EM, Tumbarello M, Caira M, Candoni A, Cattaneo C, Pastore D, Fanci R, Nosari A, Vianelli N, Busca A, et al. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica. 2011;96:e1\u20133 (author reply e4).","journal-title":"Haematologica"},{"key":"348_CR11","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2217\/fmb.12.100","volume":"7","author":"EM Trecarichi","year":"2012","unstructured":"Trecarichi EM, Cauda R, Tumbarello M. Detecting risk and predicting patient mortality in patients with extended-spectrum beta-lactamase-producing Enterobacteriaceae bloodstream infections. Future Microbiol. 2012;7:1173\u201389.","journal-title":"Future Microbiol."},{"key":"348_CR12","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3855\/jidc.6805","volume":"9","author":"A Bastug","year":"2015","unstructured":"Bastug A, Kayaaslan B, Kazancioglu S, But A, Aslaner H, Akinci E, Yetkin MA, Kanyilmaz D, Eren SS, Bodur H. Emergence of multidrug resistant isolates and mortality predictors in patients with solid tumors or hematological malignancies. J Infect Dev Ctries. 2015;9:1100\u20137.","journal-title":"J Infect Dev Ctries."},{"key":"348_CR13","unstructured":"National Comprehensive Cancer Network. Prevention and Treatment of Cancer-Related Infections (Version 1.2019). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/infections.pdf. Accessed 27 July 2019."},{"issue":"30","key":"348_CR14","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/JCO.18.00374","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston KV, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36(30):3043\u201354.","journal-title":"J Clin Oncol"},{"key":"348_CR15","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/S1473-3099(14)70780-7","volume":"14","author":"TP Van Boeckel","year":"2014","unstructured":"Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, Laxminarayan R. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14:742\u201350.","journal-title":"Lancet Infect Dis."},{"key":"348_CR16","doi-asserted-by":"publisher","first-page":"e619","DOI":"10.1016\/S2214-109X(18)30186-4","volume":"6","author":"A Versporten","year":"2018","unstructured":"Versporten A, Zarb P, Caniaux I, Gros MF, Drapier N, Miller M, Jarlier V, Nathwani D, Goossens H, Koraqi A, Hoxha I. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. Lancet Glob Health. 2018;6:e619\u201329.","journal-title":"Lancet Glob Health."},{"key":"348_CR17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1186\/s12913-018-3604-x","volume":"18","author":"A Tsutsui","year":"2018","unstructured":"Tsutsui A, Suzuki S. Japan nosocomial infections surveillance (JANIS): a model of sustainable national antimicrobial resistance surveillance based on hospital diagnostic microbiology laboratories. BMC Health Serv Res. 2018;18:799.","journal-title":"BMC Health Serv Res."},{"key":"348_CR18","doi-asserted-by":"publisher","first-page":"e39435","DOI":"10.7554\/eLife.39435","volume":"7","author":"SW Olesen","year":"2018","unstructured":"Olesen SW, Barnett ML, MacFadden DR, Brownstein JS, Hernandez-Diaz S, Lipsitch M, Grad YH. The distribution of antibiotic use and its association with antibiotic resistance. Elife. 2018;7:e39435.","journal-title":"Elife"},{"key":"348_CR19","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jiac.2018.01.003","volume":"24","author":"A Tsutsui","year":"2018","unstructured":"Tsutsui A, Yahara K, Shibayama K. Trends and patterns of national antimicrobial consumption in Japan from 2004 to 2016. J Infect Chemother. 2018;24:414\u201321.","journal-title":"J Infect Chemother."},{"key":"348_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s15010-017-1097-x","volume":"46","author":"D Yamasaki","year":"2018","unstructured":"Yamasaki D, Tanabe M, Muraki Y, Kato G, Ohmagari N, Yagi T. The first report of Japanese antimicrobial use measured by national database based on health insurance claims data (2011-2013): comparison with sales data, and trend analysis stratified by antimicrobial category and age group. Infection. 2018;46:207\u201314.","journal-title":"Infection"},{"key":"348_CR21","first-page":"524","volume":"64","author":"M Tanuma","year":"2016","unstructured":"Tanuma M, Tanaka M, Orii T. Contribution of ward pharmacists to appropriate antimicrobial use in the hematology ward. Jpn J Chemother. 2016;64:524\u20139.","journal-title":"Jpn J Chemother."},{"key":"348_CR22","doi-asserted-by":"publisher","first-page":"c2096","DOI":"10.1136\/bmj.c2096","volume":"340","author":"C Costelloe","year":"2010","unstructured":"Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ. 2010;340:c2096.","journal-title":"BMJ"},{"key":"348_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2334-14-13","volume":"14","author":"BG Bell","year":"2014","unstructured":"Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis. 2014;14:13.","journal-title":"BMC Infect Dis"},{"key":"348_CR24","first-page":"35","volume":"35","author":"S Matsuda","year":"2016","unstructured":"Matsuda S. Development of Case Mix Based Evaluation System in Japan. Jpn Hosp. 2016;35:35\u201344.","journal-title":"Jpn Hosp."},{"key":"348_CR25","unstructured":"Japan Nosocomial Infections Surveillance. JANIS Open Report 2016 (All Facilities). https:\/\/janis.mhlw.go.jp\/english\/report\/open_report\/2016\/3\/1\/ken_Open_Report_Eng_201600_clsi2012.pdf. Accessed 27 July 2019."},{"key":"348_CR26","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676\u201382.","journal-title":"Am J Epidemiol"},{"key":"348_CR27","unstructured":"AMR Clinical Reference Center. Antimicoribal agents\u2019 master. http:\/\/amrcrc.ncgm.go.jp\/surveillance\/030\/20190116rule.pdf. Accessed 27 July 2019."},{"key":"348_CR28","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/S100960100582","volume":"20","author":"A Lang","year":"2001","unstructured":"Lang A, De Fina G, Meyer R, Aschbacher R, Rizza F, Mayr O, Casini M. Comparison of antimicrobial use and resistance of bacterial isolates in a haematology ward and an intensive care unit. Eur J Clin Microbiol Infect Dis. 2001;20:657\u201360.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"348_CR29","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1093\/jac\/dkt175","volume":"68","author":"M Rajmokan","year":"2013","unstructured":"Rajmokan M, Morton A, Marquess J, Playford EG, Jones M. Development of a risk-adjustment model for antimicrobial utilization data in 21 public hospitals in Queensland, Australia (2006\u201311). J Antimicrob Chemother. 2013;68:2400\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"348_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jgar.2016.07.002","volume":"7","author":"Y Muraki","year":"2016","unstructured":"Muraki Y, Yagi T, Tsuji Y, Nishimura N, Tanabe M, Niwa T, Watanabe T, Fujimoto S, Takayama K, Murakami N, et al. Japanese antimicrobial consumption surveillance: first report on oral and parenteral antimicrobial consumption in Japan (2009\u2013-2013). J Glob Antimicrob Resist. 2016;7:19\u201323.","journal-title":"J Glob Antimicrob Resist."},{"key":"348_CR31","doi-asserted-by":"publisher","first-page":"e54190","DOI":"10.1371\/journal.pone.0054190","volume":"8","author":"Y Chong","year":"2013","unstructured":"Chong Y, Shimoda S, Yakushiji H, Ito Y, Miyamoto T, Kamimura T, Shimono N, Akashi K. Antibiotic rotation for febrile neutropenic patients with hematological malignancies: clinical significance of antibiotic heterogeneity. PLoS ONE. 2013;8:e54190.","journal-title":"PLoS ONE"},{"key":"348_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jinf.2017.10.009","volume":"76","author":"M Mikulska","year":"2018","unstructured":"Mikulska M, Averbuch D, Tissot F, Cordonnier C, Akova M, Calandra T, Ceppi M, Bruzzi P, Viscoli C, Aljurf M, Averbuch D. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J Infect. 2018;76:20\u201337.","journal-title":"J Infect"},{"key":"348_CR33","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1007\/s00520-017-3775-8","volume":"25","author":"SI Kimura","year":"2017","unstructured":"Kimura SI, Fujita H, Kato H, Hiramoto N, Hosono N, Takahashi T, Shigeno K, Hatsumi N, Minamiguchi H, Miyatake J, et al. Management of infection during chemotherapy for acute leukemia in Japan: a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group. Support Care Cancer. 2017;25:3515\u201321.","journal-title":"Support Care Cancer"},{"key":"348_CR34","first-page":"1308","volume":"60","author":"LA Hicks","year":"2015","unstructured":"Hicks LA, Bartoces MG, Roberts RM, Suda KJ, Hunkler RJ, Taylor TH Jr, Schrag SJ. US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. Clin Infect Dis. 2015;60:1308\u201316.","journal-title":"Clin Infect Dis"},{"key":"348_CR35","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.amjmed.2010.03.021","volume":"123","author":"BC Pien","year":"2010","unstructured":"Pien BC, Sundaram P, Raoof N, Costa SF, Mirrett S, Woods CW, Reller LB, Weinstein MP. The clinical and prognostic importance of positive blood cultures in adults. Am J Med. 2010;123:819\u201328.","journal-title":"Am J Med"},{"key":"348_CR36","unstructured":"Mimura W, Fukuda H, Konomura K, Akazawa M. Assessment of record linkage using administrative claims data and antimicrobial susceptibility testing data. ISPE\u2019s 12 the Asian Conference on Pharmacoepidemiology and 25th Japanese Conference on Pharmacoepidemiology joint meeting. 2019. Kyoto, Japan. http:\/\/www.jtbw-mice.com\/acpe2019\/data\/pdf\/poster_abstracts_ACPE2019.pdf. Accessed 26 Dec 2019."}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-020-00348-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12941-020-00348-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-020-00348-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T16:25:24Z","timestamp":1613579124000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-020-00348-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,17]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["348"],"URL":"https:\/\/doi.org\/10.1186\/s12941-020-00348-0","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,17]]},"assertion":[{"value":"10 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the institutional review board of Meiji Pharmaceutical University (No. 3007). The provision and analysis of DPC and JANIS data was approved by the Kyushu University Institutional Review Board for Clinical Research (29\u2013364). Informed consent was not required from the patients, because the study was a retrospective analysis using anonymized data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HF reports fees from Astellas Pharma, Inc., Nippon Becton\u2013Dickinson Co., Ltd, Novartis Pharma K.K., Pfizer, Inc., MA reports fees from Janssen Pharmaceutical K.K., Takeda Pharmaceuticals, Inc., and Pfizer, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}